Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Obstetrics and Gynecology Reports
Erschienen in: Current Obstetrics and Gynecology Reports 2/2017

29.04.2017 | Reproductive Endocrinology and Infertility (REI) (R Anchan, Section Editor)

Genetic Screening and Early Recurrent Pregnancy Loss

verfasst von: Paul R. Brezina

Erschienen in: Current Obstetrics and Gynecology Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to identify current data and provide a clear treatment path specifically the role of preimplantation genetic screening (PGS) for the evaluation and treatment of recurrent early pregnancy loss (RPL).

Recent Findings

Recent data within the causes of RPL have established that the role of genetics, specifically chromosomal aneuploidy, is far more significant as a cause of the disorder than has been traditionally believed. Current data suggests that at least 50% of all first trimester losses are a result of such chromosomal copy number errors. Furthermore, therapeutic techniques, such as Preimplantation Genetic Screening (PGS) are now available to reduce the chances of aneuploidy in appropriately selected couples with RPL.

Summary

Recurrent early pregnancy loss (RPL) represents a significant challenge for many couples wishing to grow their family. The clinical management of RPL is challenging given the multiple causes of pregnancy loss. The past several decades have seen tremendous advances in the understanding of and treatment for this heterogeneous disorder. Thankfully, a definite cause of pregnancy loss can be established in over half of couples after a thorough evaluation. The evaluation of RPL may be conducted in a structured manner, focusing on a defined set of etiological categories including anatomic, genetic, immunologic, endocrinologic, infectious, and environmental.
Literatur
1.
Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98(5):1103–11.
2.
Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril. 2013;99(1):63.
3.
Brezina PR, Kutteh WH. Classic and cutting-edge strategies for the Management of Early Pregnancy Loss. Obstet Gynecol Clin N Am. 2014;41(1):1–18.CrossRef
4.
Jaslow CR, Carney JL, Kutteh WH. Diagnostic factors identified in 1020 women with two versus three or more recurrent pregnancy losses. Fertil Steril. 2010;93(4):1234–43.CrossRefPubMed
5.
Lund M, Kamper-Jorgensen M, Nielsen HS, Lidegaard O, Andersen AM, Christiansen OB. Prognosis for live birth in women with recurrent miscarriage: what is the best measure of success? Obstet Gynecol. 2012;119(1):37–43.CrossRefPubMed
6.
Stirrat GM. Recurrent miscarriage. Lancet (London, England). 1990;336(8716):673–5.CrossRef
7.
Bernardi LA, Plunkett BA, Stephenson MD. Is chromosome testing of the second miscarriage cost saving? A decision analysis of selective versus universal recurrent pregnancy loss evaluation. Fertil Steril. 2012;98(1):156–61.CrossRefPubMed
8.
Foyouzi N, Cedars MI, Huddleston HG. Cost-effectiveness of cytogenetic evaluation of products of conception in the patient with a second pregnancy loss. Fertil Steril. 2012;98(1):151–5.CrossRefPubMed
9.
Jaslow CR. Uterine factors. Obstet Gynecol Clin N Am. 2014;41(1):57–86.CrossRef
10.
Shahine L, Lathi R. Recurrent pregnancy loss: evaluation and treatment. Obstet Gynecol Clin N Am. 2015;42(1):117–34.CrossRef
11.
Ke RW. Endocrine basis for recurrent pregnancy loss. Obstet Gynecol Clin N Am. 2014;41(1):103–12.CrossRef
12.
De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(8):2543–65.CrossRefPubMed
13.
Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, et al. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med. 2015;373(22):2141–8.CrossRefPubMed
14.
Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584–9.CrossRefPubMed
15.
Ghazeeri GS, Kutteh WH. Immunological testing and treatment in reproduction: frequency assessment of practice patterns at assisted reproduction clinics in the USA and Australia. Human reproduction (Oxford, England). 2001;16(10):2130–5.CrossRef
16.
Kutteh WH, Lyda EC, Abraham SM, Wacholtz MC. Association of anticardiolipin antibodies and pregnancy loss in women with systemic lupus erythematosus. Fertil Steril. 1993;60(3):449–55.CrossRefPubMed
17.
Ernest JM, Marshburn PB, Kutteh WH. Obstetric antiphospholipid syndrome: an update on pathophysiology and management. Semin Reprod Med. 2011;29(6):522–39.CrossRefPubMed
18.
Han CS, Mulla MJ, Brosens JJ, Chamley LW, Paidas MJ, Lockwood CJ, et al. Aspirin and heparin effect on basal and antiphospholipid antibody modulation of trophoblast function. Obstet Gynecol. 2011;118(5):1021–8.CrossRefPubMedPubMedCentral
19.
Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Human reproduction (Oxford, England). 1997;12(9):2061–5.CrossRef
20.
• Kutteh WH. Antiphospholipid antibody syndrome and reproduction. Current opinion in obstetrics & gynecology. 2014;26(4):260–5. This article outlines the immunological role of antiphospholipid antibodies within the context of RPL. CrossRef
21.
Empson M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol. 2002;99(1):135–44.PubMed
22.
Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? American journal of reproductive immunology (New York, NY : 1989). 2012;67(4):296–304.CrossRef
23.
Jablonowska B, Selbing A, Palfi M, Ernerudh J, Kjellberg S, Lindton B. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Human reproduction (Oxford, England). 1999;14(3):838–41.CrossRef
24.
Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: aetiology, management and prognosis. Hum Reprod Update. 2002;8(5):463–81.CrossRefPubMed
25.
Stephenson MD, Kutteh WH, Purkiss S, Librach C, Schultz P, Houlihan E, et al. Intravenous immunoglobulin and idiopathic secondary recurrent miscarriage: a multicentered randomized placebo-controlled trial. Human reproduction (Oxford, England). 2010;25(9):2203–9.CrossRef
26.
Wong LF, Porter TF, Scott JR. Immunotherapy for recurrent miscarriage. The Cochrane database of systematic reviews. 2014;10:Cd000112.
27.
Lockwood C, Wendel G. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol. 2011;118(3):730–40.CrossRefPubMed
28.
Kutteh WH. Inherited and acquired Thrombophilias and adverse pregnancy outcomes. Recurrent Pregnancy Loss: Springer; 2016. p. 67–74.
29.
Penta M, Lukic A, Conte MP, Chiarini F, Fioriti D, Longhi C, et al. Infectious agents in tissues from spontaneous abortions in the first trimester of pregnancy. The new microbiologica. 2003;26(4):329–37.PubMed
30.
Philipp T, Philipp K, Reiner A, Beer F, Kalousek DK. Embryoscopic and cytogenetic analysis of 233 missed abortions: factors involved in the pathogenesis of developmental defects of early failed pregnancies. Human reproduction (Oxford, England). 2003;18(8):1724–32.CrossRef
31.
Du L, Brezina P, Benner A, Swelstad B, Gunn M, Kearns W. The rate of de novo and inherited aneuploidy as determined by 23-chromosome single nucleotide polymorphism microarray (SNP) in embryos generated from parents with known chromosomal translocations. Fertil Steril. 2011;96(3):S221.CrossRef
32.
Horvat S, McWhir J, Rozman D. Defects in cholesterol synthesis genes in mouse and in humans: lessons for drug development and safer treatments. Drug Metab Rev. 2011;43(1):69–90.CrossRefPubMed
33.
•• Brezina PR, Kutteh WH. Clinical applications of preimplantation genetic testing. BMJ (Clinical research ed). 2015;350:g7611. This article serves as a summary of the state of the art of preimplantation genetic testing as part of the state of the art review series published by the British Medical Journal.
34.
Nayak S, Pavone ME, Milad M, Kazer R. Aneuploidy rates in failed pregnancies following assisted reproductive technology. Journal of women’s health (2002). 2011;20(8):1239–43.CrossRef
35.
Technology PCotASfRMatSfAR. ASRM Practice Committee Brief Communication on Pre-Implantation Genetic Screening for Aneuploidy: a committee opinion. 2016.
36.
Brezina PR, Kearns WG. The evolving role of genetics in reproductive medicine. Obstet Gynecol Clin N Am. 2014;41(1):41–55.CrossRef
37.
Brezina P, Tobler K, Benner A, Du L, Boyd B, Kearns W. Evaluation of 571 in vitro fertilization (IVF) Cycels and 4,873 embryos using 23-chromosome single nucleotide polymorphism (SNP) microarray preimplantation genetic screening (PGS). Fertil Steril. 2012;97(3):S23–S4.
38.
Wells D, Alfarawati S, Fragouli E. Use of comprehensive chromosomal screening for embryo assessment: microarrays and CGH. Mol Hum Reprod. 2008;14(12):703–10.CrossRefPubMedPubMedCentral
39.
Brezina PR, Kutteh WH, Bailey AP, Ding J, Ke RW, Klosky JL. Fertility preservation in the age of assisted reproductive technologies. Obstet Gynecol Clin N Am. 2015;42(1):39–54.CrossRef
40.
Brezina PR, Ross R, Kaufmann R, Anchan R, Zhao Y, Kearns WG. Genetic normalization of differentiating aneuploid cleavage stage embryos. Fertil Steril. 2013;100(3, Supplement):S69.CrossRef
41.
Harper JC, Wilton L, Traeger-Synodinos J, Goossens V, Moutou C, SenGupta SB, et al. The ESHRE PGD consortium: 10 years of data collection. Hum Reprod Update. 2012;18(3):234–47.CrossRefPubMed
42.
Brezina P, Nguyen K, Benner A, Du L, Ross R, Barker A, et al., editors. Aneuploid blastomeres may undergo a process of genetic normalization resulting in euploid blastocysts. HUMAN REPRODUCTION. GREAT CLARENDON ST: OXFORD UNIV PRESS; 2011.
43.
Munne S, Weier HU, Grifo J, Cohen J. Chromosome mosaicism in human embryos. Biol Reprod. 1994;51(3):373–9.CrossRefPubMed
44.
•• Brezina PR, Kutteh WH, Bailey AP, Ke RW. Preimplantation genetic screening (PGS) is an excellent tool, but not perfect: a guide to counseling patients considering PGS. Fertil Steril. 2016;105(1):49–50. This article outlines the risks and limitations of PGS and provides clinicians a practical guide on how to counsel patients considering PGS. CrossRefPubMed
45.
Dahdouh EM, Balayla J, Audibert F, Wilson RD, Audibert F, Brock JA, et al. Technical update: preimplantation genetic diagnosis and screening. Journal of obstetrics and gynaecology Canada : JOGC =. Journal d’obstetrique et gynecologie du Canada : JOGC. 2015;37(5):451–63.CrossRefPubMed
46.
Schoolcraft WB, Fragouli E, Stevens J, Munne S, Katz-Jaffe MG, Wells D. Clinical application of comprehensive chromosomal screening at the blastocyst stage. Fertil Steril. 2010;94(5):1700–6.CrossRefPubMed
Metadaten
Titel
Genetic Screening and Early Recurrent Pregnancy Loss
verfasst von
Paul R. Brezina
Publikationsdatum
29.04.2017
Verlag
Springer US
Erschienen in
Current Obstetrics and Gynecology Reports / Ausgabe 2/2017
Elektronische ISSN: 2161-3303
DOI
https://doi.org/10.1007/s13669-017-0207-1

Weitere Artikel der Ausgabe 2/2017

Current Obstetrics and Gynecology Reports 2/2017 Zur Ausgabe

Care for the Transgender Patient (C Unger, Section Editor)

Hysterectomy for the Transgender Man

Family Planning (A Burke, Section Editor)

Non-Contraceptive Benefits of Hormonal Contraception: Established Benefits and New Findings

Emerging and Pipeline Technologies in Ob/Gyn (M Levie, Section Editor)

A High-Strength, Absorbable, Antibacterial Knotless Tissue Control Device for Fascial Closure

Care for the Transgender Patient (C Unger, Section Editor)

Gynecologic Care for Transgender Adults

Care for the Transgender Patient (C Unger, Section Editor)

Reproductive and Obstetrical Care for Transgender Patients

Family Planning (A Burke, Section Editor)

Unscheduled Bleeding on Hormonal Contraceptives: Pathophysiology, Evaluation, and Management Options

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Embryotransfer erhöht womöglich Leukämierisiko der Kinder

13.05.2024 Assistierte Reproduktion Nachrichten

Reproduktionsmedizinische Techniken haben theoretisch das Potenzial, den epigenetischen Code zu verändern und somit das Krebsrisiko der Kinder zu erhöhen. Zwischen Embryotransfer und Leukämie scheint sich ein solcher Zusammenhang bestätigt zu haben.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise